Interest in the psychedelic market is as high as Matt Gaetz and Joel Greenberg on a night out, but the accompanying FOMO has the potential… Read More »From Leary’s lunacy to a legitimate lab – psychedelics sector in review
The psychedelics space is one of the hottest investment trips in the public markets today. Embryonic, wide open to possibility and with mounting scientific evidence… Read More »Loving the light fantastic – psychedelics sector in review
Numinus Wellness (NUMI.V) announced today that it has closed its acquisition of the Neurology Centre of Toronto (NCT). “NCT by Numinus represents an important paradigm… Read More »Numinus Wellness (NUMI.V) to Open Clinical Neurology Centre, Completes Acquisition of NCT
MAPS, FDA & Health Canada In a highly regulated sector like psychedelics, governing bodies like the FDA and Health Canada have the power to shape… Read More »From trials to dealers licenses – how Health Canada has really helped out Numinus (NUMI.V)
Numinus Wellness (NUMI.V) announced that Health Canada has cleared their MAPS-sponsored single-arm, open-label safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD).
Numinus Wellness (NUMI.V) announced that Health Canada has cleared their MAPS-sponsored single-arm, open-label safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD).… Read More »Numinus Wellness (NUMI.V) is cleared by Health Canada to work with MAPS on MDMA therapy for PTSD
Numinus Wellness (NUMI.V) announced they are going to acquire Neurology Centre of Toronto (NCT), pursuant to a purchase agreement from July 2, 2021. To acquire… Read More »Numinus (NUMI.V) to acquire Neurology Centre of Toronto (NCT)
Numinus Wellness (NUMI.V) and Optimi Health (OPTI.C) announced they have submitted a pre-clinical trial application to Health Canada. The application was submitted through Impact Clinical… Read More »Numinus (NUMI.V) and Optimi (OPTI.C) submit pre-clinical trial application to Health Canada
Numinus Wellness (NUMI.V) partnered with KGK Science, a contract research organization focusing on natural products, for a few psilocybin extraction clinical trial today, according to… Read More »Numinus Wellness (NUMI.V) and researcher KGK Science engage in Phase 1 psychedelics trial
Numinus (NUMI.V) is gaining somewhat of a cult-like following among retail investors. People see an undervalued company with competitive advantages, and from an ethics… Read More »Why retail investors are super bullish on Numinus (NUMI.V)
